热搜词：
注册
登录
CN
  • CN
  • EN

产品中心 蛋白 细胞因子

所有图片（1/3）

BMP-2 Protein, Human/Mouse/Rat

Bone morphogenetic protein 2,BMP-2,Bone morphogenetic protein 2A (BMP-2A)

价格 ￥900.00 （ 供应商现货 ： 3-5个工作日）
货号 UA040572
规格
数量
收藏 分享
产品介绍

产品介绍 评论(0)

产品规格

  • 分子别名

    Bone morphogenetic protein 2, BMP-2, Bone morphogenetic protein 2A (BMP-2A)

  • Accession

    P12643

  • 表达序列

    Leu284-Arg396

  • 表达宿主

    CHO

  • 分子量

    14-16 kDa (Reducing)

  • 纯度

    >95% by SDS-PAGE.

  • 内毒素含量

    <0.1EU/μg

  • 活性

    EC50 = 100-144 ng/ml

  • 标记

    Unconjugated

  • 标签

    No Tag

  • 性状

    Lyophilized Powder

  • 缓冲体系

    4mM HCl

  • 溶解方法

    Reconstitute at 0.1-1 mg/ml according to the size in Reconstitution Buffer after rapid centrifugation.

  • 储存条件

    ·12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
    ·3 months, -20 to -80℃ under sterile conditions after reconstitution.
    ·1 week, 2 to 8℃ under sterile conditions after reconstitution.
    ·Please avoid repeated freeze-thaw cycles.

  • 文献引用

    Bone: formation by autoinduction. Science 150, 893–899 (1965).
    Novel regulators of bone formation: molecular clones and activities. Science 242, 1528–1534 (1988).

背景介绍

  • Bone morphogenetic protein 2 (BMP-2) is a multifunctional growth factor belonging to the transforming growth factor-β (TGF-β) superfamily. The osteoinductive activity of bone-derived proteins was first described by Marshall Urist in 1965. As one of the most potent osteoinductive factors known, BMP-2 initiates the differentiation of mesenchymal stem cells into osteoblasts and chondrocytes, playing essential roles in embryonic skeletal development, bone remodeling, and fracture healing.

    In the biomedical industry, rhBMP-2 received FDA approval in 2002 and is commercially available as the Infuse™ Bone Graft system, delivered via an absorbable collagen sponge carrier. Industrial applications are predominantly focused on spinal fusion surgeries, where rhBMP-2 has demonstrated fusion rates comparable to or higher than autologous bone grafts. Additional clinical indications include open tibial fractures, maxillofacial reconstruction, sinus augmentation, and treatment of femoral head necrosis. However, clinical use is constrained by dose-dependent complications including inflammation, ectopic ossification, osteolysis, and concerns regarding cost and safety.

  • 生物活性

    • Determined by its ability to induce alkaline phosphatase production by ATDC-5 cells. The expected EC50 for this effect is 100-144 ng/ml.

    • Measured by its ability to induce BMP-2 responsive firefly luciferase reporter activity in HEK293T human embryonic kidney cells. The expected EC50 for this effect is 0.38-3.3 ng/ml.

  • 电泳

    • 2μg (R: reducing condition, N: non-reducing condition).

评论(0)